Gene · 338413
Papers2,372
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 2,372
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. | EMBO Mol Med | 2023 | 36722641 | PubTator, text mining | PubMed |
| Epithelial cell-derived cytokine TSLP activates regulatory T cells by enhancing fatty acid uptake. | Sci Rep | 2023 | 36717741 | PubTator, text mining | PubMed |
| Factors in rural community buprenorphine dispensing. | Explor Res Clin Soc Pharm | 2023 | 36703716 | PubTator, text mining | PubMed |
| Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors. | Cell Death Dis | 2023 | 36702816 | PubTator, text mining | PubMed |
| Ultra-Low Level Somatic Mutations and Structural Variations in Focal Cortical Dysplasia Type II. | Ann Neurol | 2023 | 36700525 | PubTator, text mining | PubMed |
| Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma. | Mol Cancer Ther | 2023 | 36696581 | PubTator, text mining | PubMed |
| Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway. | Cell Death Dis | 2023 | 36681687 | PubTator, text mining | PubMed |
| Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs. | Cell Transplant | 2023 | 36661068 | PubTator, text mining | PubMed |
| Targeted therapy for head and neck cancer: signaling pathways and clinical studies. | Signal Transduct Target Ther | 2023 | 36646686 | PubTator, text mining | PubMed |
| Localized heterochrony integrates overgrowth potential of oncogenic clones. | Dis Model Mech | 2023 | 36621776 | PubTator, text mining | PubMed |
| Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry. | J Biol Chem | 2023 | 36596361 | PubTator, text mining | PubMed |
| Rapamycin improves Graves' orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. | JCI Insight | 2023 | 36580373 | PubTator, text mining | PubMed |
| Infiltration of Tumors Is Regulated by T cell-Intrinsic Nitric Oxide Synthesis. | Cancer Immunol Res | 2023 | 36574610 | PubTator, text mining | PubMed |
| PTPN11 Mosaicism Causes a Spectrum of Pigmentary and Vascular Neurocutaneous Disorders and Predisposes to Melanoma. | J Invest Dermatol | 2023 | 36566878 | PubTator, text mining | PubMed |
| Proteomics reveals that cell density could affect the efficacy of drug treatment. | Biochem Biophys Rep | 2023 | 36561432 | PubTator, text mining | PubMed |
| Growth arrest and DNA damage-inducible alpha regulates muscle repair and fat infiltration through ATP synthase F1 subunit alpha. | J Cachexia Sarcopenia Muscle | 2023 | 36511343 | PubTator, text mining | PubMed |
| Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. | Clin Transl Oncol | 2023 | 36508123 | PubTator, text mining | PubMed |
| Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. | Clin Cancer Res | 2023 | 36477181 | PubTator, text mining | PubMed |
| Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells. | Blood Adv | 2023 | 36453632 | PubTator, text mining | PubMed |
| Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia. | Haematologica | 2023 | 36420798 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/338413/papers?page=14